Surotomycin was an investigational oral antibiotic. This macrolide antibiotic was under investigation by Merck & Co (who acquired Cubist Pharmaceuticals) for the treatment of life-threatening diarrhea, commonly caused by the bacterium Clostridioides difficile.[1] After reaching phase III in clinical trials, its production was discontinued in 2017 due to its non-superiority to current therapies.[2][3]
See also
References
- ^ "Surotomycin Fact Sheet" (PDF). cubist.com.
- ^ P Daley; T Louie; J E Lutz; S Khanna; U Stoutenburgh; M Jin; A Adedoyin; L Chesnel; D Guris; K B Larson; Y Murata (December 2017). "Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial". Journal of Antimicrobial Chemotherapy. 72 (12): 3462–3470. doi:10.1093/jac/dkx299. PMID 28961905.
- ^ Jenna Payesko. "Surotomycin Fails To Show Benefit Over Vancomycin in C. Difficile Treatment in Phase 3 Trial". MD magazines. Retrieved 24 September 2019.